Right to Try Clarification Act
- Last Action
- 4/7/2023
Actions
- 2023-04-07Referred to the Subcommittee on Health.
- 2023-03-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-03-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-03-28Sponsor introductory remarks on measure. (CR E267)
- 2023-03-28Introduced in House
- 2023-03-28Introduced in House
CRS Summary
As of 2023-03-28 (00)
Right to Try Clarification Act
This bill specifies that investigational drugs that are provided via the Right to Try pathway are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).
The Right to Try pathway allows drug manufacturers to provide certain investigational drugs for which a Phase I clinical trial has been completed, but that have not yet received approval from the Food and Drug Administration, directly to individuals who have imminently life-threatening diseases or conditions and who have exhausted other treatment options and are unable to participate in clinical trials.
Cosponsors (4)
- Nancy Mace (R-SC)
- Madeleine Dean (D-PA)
- Andy Biggs (R-AZ)
- J. Correa (D-CA)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.